Cancer feature: cnaPANCAN71

ACCS ACCSL ACP2 AGBL2 ALKBH3 ALX4 AMBRA1 API5 ARFGAP2 ARHGAP1 ATG13 C11orf49 C11orf94 C11orf96 C1QTNF4 CD82 CELF1 CHRM4 CHST1 CKAP5 CREB3L1 CRY2 CTD-2210P24.4 DGKZ EXT2 F2 FAM180B FNBP4 FOLH1 GYLTL1B HARBI1 HSD17B12 KBTBD4 LRP4 LRRC4C MADD MAPK8IP1 MDK MTCH2 MYBPC3 NDUFS3 NR1H3 NUP160 OR4A47 OR4B1 OR4C12 OR4C13 OR4C3 OR4C5 OR4S1 OR4X1 OR4X2 PACSIN3 PEX16 PHF21A PRDM11 PSMC3 PTPMT1 PTPRJ RAPSN SLC35C1 SLC39A13 SPI1 SYT13 TP53I11 TRIM64C TSPAN18 TTC17 ZNF408

Known Driver Genes: EXT2

Copy number alternation: loss

UNC0379

The Genomics of Drug Sensitivity in Cancer Project is a collaboration between the Cancer Genome Project at the Wellcome Sanger Institute (UK) and the Center for Molecular Therapeutics, Massachusetts General Hospital Cancer Center (USA). This work is funded by Wellcome.

Users have a non-exclusive, non-transferable right to use data files for internal proprietary research and educational purposes, including target, biomarker and drug discovery. Excluded from this licence are use of the data (in whole or any significant part) for resale either alone or in combination with additional data/product offerings, or for provision of commercial services.
Please note: The data files are experimental and academic in nature and are not licensed or certified by any regulatory body. Genome Research Limited provides access to data files on an “as is” basis and excludes all warranties of any kind (express or implied).

Genomics of Drug Sensitivity in Cancer